Research program
Evidence, Economics, and Rights
This program sets out the evidence, economics, rights, and decision rules that make a care model worth pursuing and safe to sustain. A care model can advance only when its scientific, market, adoption, economic, and strategic claims survive separate review, because strength in one track cannot erase a fatal weakness in another.
What evidence, economics, rights, and decision rules make the care model worth pursuing and safe to sustain?
Keep five evidence tracks separate
Scientific evidence asks whether the mechanism or intervention works. Market evidence asks whether someone will commit scarce resources. Adoption evidence asks whether the intervention can enter routine workflow. Economic evidence asks whether value is created and can be captured. Strategic evidence asks whether a durable advantage exists.
Strength in one track cannot erase a fatal weakness in another. A good clinical result does not prove payment. A signed pilot does not prove repeat use. A patent does not prove demand.
Match evidence to the claim
Technical performance, clinical validity, utility, workflow improvement, economic value, and patient outcome are separate claims. Each needs evidence suited to it. The record should show the source, date, quality, contradictions, and practical consequence.
Evidence becomes stronger as a stakeholder gives up something scarce: data, access, clinician time, workflow control, procurement effort, money, or reputation. Positive interviews and letters of support sit below implementation, repeat use, payment, measured outcomes, and replication.
Follow the economics
Map the clinical beneficiary, economic beneficiary, purchaser, approver, user, patient, data owner, and risk bearer. They are often different. Then estimate the cost of finding the patient, preparing care, implementing the workflow, operating the intervention, and handling exceptions.
Value may come from improved response, wider eligibility, fewer complications, lower administrative burden, avoided hospital use, or increased treatment revenue. The model must say who can measure that value and what share can realistically be captured through reimbursement, licensing, service fees, shared savings, or another arrangement.
Rights need a commercial job
The relevant assets may include a mechanism, patient-selection method, readiness measure, conditioning intervention, sequence, monitoring logic, workflow, data structure, know-how, implementation method, or access right. Ownership, inventorship, freedom to operate, enforceability, and demand are different questions.
Data rights require particular care. The record should state permitted use, consent, contractual limits, reuse, model training, publication, and learning across institutions. Prefer the narrowest rights needed for the intended route. Do not acquire control merely because control is available.
Use base rates and counterfactuals
Before explaining why an opportunity will succeed, examine how comparable therapies, devices, hospital pilots, care models, reimbursement paths, and funded discoveries usually perform. Native Alpha™ should explain why this case may beat that base rate. It should not make the base rate disappear.
Outcome claims also need a credible comparison. Ask what would have happened under current care, the current workflow, a matched cohort, or a plausible alternative. Do not assign causal credit because a metric changed after implementation.
Write the failure case first
Define what would disprove the mechanism, adoption, reimbursement, buyer, rights, market, useful AI contribution, and data-compounding claims before large investment. Name the threshold, not just the risk.
The next experiment should reduce the most important uncertainty at the lowest reasonable cost. A reimbursement review may kill an idea before a pilot. A cohort query may settle patient access before product development. A request for data or workflow access tests behavior more directly than asking whether someone is interested.
Evidence expires
Healthcare evidence changes with spending, coverage, guidelines, trials, regulatory status, competition, provider ownership, and workforce conditions. Every material item needs an observed date, expected useful life, source refresh cadence, and revalidation date.
Unsupported, stale, single-source, unreplicated, or unresolved claims create evidence debt. The debt register should show the risk if a claim is wrong, the owner, the resolution method, the deadline, and which decision it blocks.
Replicate before scaling
One successful site, clinician, geography, payer, or patient cohort does not establish scale. Test at least one meaningful change in setting, and more than one for high-consequence work. Implementation without founder involvement is often an important test.
A project should always have one current state: investigate, validate, pilot, scale, partner, license, incubate, monitor, or stop. It also needs one owner, one next test, and one next decision.
Decision package
The final record should make disagreement possible. Missing evidence stays visible. A recommendation that does not change action or justify deliberate monitoring should stop.
| Part | Question | Boundary |
|---|---|---|
| Hypothesis | What is believed? | State it so it can fail |
| Evidence | What supports and contradicts it? | Keep tracks separate |
| Base rate | How do similar efforts perform? | Explain any claimed exception |
| Economics | Who pays, saves, earns, and bears cost? | Use realistic capture |
| Rights | What control is actually required? | Do not infer legal conclusions |
| Kill criteria | What result ends the work? | Set before sunk cost grows |
| Next test | What is the cheapest useful test? | Tie it to a decision |
Research notes
Care model decision package
Bring the hypothesis, evidence, economics, rights, uncertainty, failure case, and next decision into one reviewable record. The package lets a reviewer decide on a care model with every material claim and every missing answer in view, instead of an average that hides a fatal weakness.
Cheapest next test
This note says to pick the smallest observable test that could reverse the decision, and to prefer behavior over interest. A reader gains a cheaper way to settle the assumption that matters most, and no larger experiment should be funded when a smaller one can invalidate it. Reduce the most important uncertainty with the least time, money, access, and patient exposure reasonably required.
Evidence debt register
Make stale, weak, unsupported, single-source, and unresolved claims visible before they quietly drive decisions. The register records each claim's evidence status, risk if wrong, owner, and decision blocked, so debt that can reverse a clinical, economic, rights, or adoption decision is resolved first.
Evidence ladder
Rank evidence by the scarce real-world commitment it reflects, from public signal through replicated outcome. The ladder lets a reader state which rung supports each claim and what next commitment would materially change confidence, instead of treating all evidence as equal.
Related
- Consumer tech for medical grade devices
- Intermediation in Healthcare Delivery
- From Product to Rights
- Care model decision package